Hypopharyngeal Cancer Treatment Delays: Benchmarks and Survival Association
Morse E, Berson E, Fujiwara R, Judson B, Mehra S. Hypopharyngeal Cancer Treatment Delays: Benchmarks and Survival Association. Otolaryngology 2018, 160: 267-276. PMID: 30324861, DOI: 10.1177/0194599818797605.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenchmarkingCarcinoma, Squamous CellChemoradiotherapyCohort StudiesDisease-Free SurvivalFemaleHumansHypopharyngeal NeoplasmsLogistic ModelsMaleMiddle AgedMultivariate AnalysisPrognosisProportional Hazards ModelsRadiotherapy, ConformalRetrospective StudiesRisk AssessmentSurvival AnalysisTime-to-TreatmentTreatment OutcomeConceptsRadiation treatment durationOverall survivalInduction chemotherapyMedian durationConcurrent chemoradiationHypopharyngeal cancerCox proportional hazards regressionNational Cancer DatabaseProportional hazards regressionMultivariable logisticRetrospective cohortTreatment initiationMedicaid insuranceTreatment delayCancer HospitalHazards regressionNonwhite raceCancer DatabaseTreatment endSurvival associationsTreatment durationPatientsChemoradiationChemotherapyTreatment factorsSurvival Outcomes for Induction vs Adjuvant Chemotherapy in Squamous Cell Carcinoma of the Maxillary Sinus
Kuo P, Torabi SJ, Kraus D, Judson BL. Survival Outcomes for Induction vs Adjuvant Chemotherapy in Squamous Cell Carcinoma of the Maxillary Sinus. Otolaryngology 2018, 160: 658-663. PMID: 30296902, DOI: 10.1177/0194599818804777.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseAdjuvant chemotherapyMultivariate Cox regressionInduction chemotherapyLog-rank testMaxillary sinus cancerOverall survivalCox regressionSinus cancerMaxillary sinusUnivariate Kaplan-Meier analysisPoor local control ratesAdvanced maxillary sinus cancerAdjuvant chemotherapy cohortImproved overall survivalLocal control rateMortality hazard ratioKaplan-Meier analysisSquamous cell carcinomaSignificant mortality hazard ratiosSecondary database analysisWarrants further investigationPropensity-score matchingChemotherapy cohortHazard ratio